Mesa Laboratories, Inc. (MLAB) AI Stock Analysis

Mesa Laboratories, Inc. specializes in the development, manufacturing, and global distribution of life sciences tools and quality control products and services. Headquartered in Lakewood, Colorado, it operates across segments including Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. Its Sterilization and Disinfection Control unit produces biological, cleaning, and chemical indicators alongside dental laboratory testing services. The Biopharmaceutical Development segment offers automated protein analysis systems and peptide synthesizers for therapeutic treatments, biomaterials, and research. Its Calibration Solutions segment designs quality control and calibration devices measuring parameters such as temperature, pressure, pH, and humidity for hospitals, pharmaceutical facilities, and medical device manufacturing environments.

Mesa Laboratories expanded revenue from $184.3M in FY2022 to $249.1M in FY2026, delivering a 5-year revenue compound annual growth rate of 13.2%. Gross margin expanded consistently from 59.2% in FY2022 to 63.5% in FY2026. Operating performance experienced volatility, swinging from an operating margin of -125.9% and net income of -$254.2M in FY2024 to an operating margin of 7.4% and net income of $6.7M in FY2026. In the latest quarter ended June 30, 2026, quarterly revenue grew 1.0% year-over-year, while quarterly earnings declined 42.4%. For the trailing twelve months, operating margin was 11.7% on $249.7M of revenue.

As of June 30, 2026, Mesa Laboratories held $30.7M in cash and short-term investments against total debt of $101.4M, resulting in net debt of $70.7M. Shareholders' equity was $188.8M with total assets of $419.2M. The company maintains a current ratio of 2.07 and a debt-to-equity ratio of 0.54. Operating cash flow stood at $42.8M in FY2026, supporting free cash flow of $39.6M. Capital allocation in FY2026 included capital expenditures of $3.2M and dividends paid of $3.5M.

At a last close of $122.48, Mesa Laboratories has a market capitalization of $685.4M and an enterprise value of $868.2M. The stock trades at a trailing price-to-earnings ratio of 144.1x and a forward P/E of 34.5x, compared to the median of its US-listed Technology peers of 28.1x and 18.8x, respectively. Its enterprise value-to-EBITDA ratio is 20.1x compared to the peer median of 16.6x, while its price-to-sales multiple of 2.7x is near the peer median of 2.8x. Over the past year, the stock returned 66.2%, outperforming the S&P 500 (SPY) return of 16.8%, but its 5-year return of -59.4% lags the index return of 83.0%.

Mesa Laboratories pays a quarterly dividend with an annualized forward payout of $0.64 per share, offering a dividend yield of 0.52%. The payout ratio is 8.1%. Mesa Laboratories has paid dividends for 24 consecutive years, though its 5-year annualized dividend growth is 0.0%. Its last ex-dividend date is November 30, 2026.

Wall Street coverage consists of 1 Strong Buy and 1 Hold rating. The mean price target of $125.00 represents a 2.1% premium over the last close of $122.48. For the fiscal year ending March 31, 2027, consensus estimates project revenue of $254.4M and EPS of $9.95, representing 19.2% earnings growth. Over the last 4 quarters, the company beat EPS estimates 3 times. The next earnings date is November 5, 2026.

This page is an AI-written research summary of Mesa Laboratories, Inc. (MLAB). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MLAB income statement, MLAB balance sheet, MLAB key metrics, MLAB analyst forecast, MLAB chart. See the MLAB stock overview for the latest quote and news.